Treatment of Subclinical Hyperthyroidism

NCT ID: NCT00213720

Last Updated: 2020-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

145 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-08-31

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective: To determine if the treatment of subclinical hyperthyroidism will reduce the rate of atrial fibrillation, the main complication of this condition.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Randomized open-labelled multicentre study comparing radioiodine vs medical supervision without treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subclinical Hyperthyroidism Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged 50 and greater
* Isolated decreased thyroid-stimulating hormone (TSH) with normal FT4 and FT3 levels

Exclusion Criteria

* Iodide overload
* Non sinusal heart rhythm
* Severe heart disease
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bernard Goichot, MD

Role: PRINCIPAL_INVESTIGATOR

Hopitaux Universitaires de Strasbourg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Patrick Roger

Bordeaux, , France

Site Status

Philippe Thiéblot

Clermont-Ferrand, , France

Site Status

Jean-Marcel Brun

Dijon, , France

Site Status

Jean-Louis Wemeau

Lille, , France

Site Status

Marie-Pierre Teissier

Limoges, , France

Site Status

Jacques Orgiazzi

Lyon, , France

Site Status

Bernard Conte-Delvox

Marseille, , France

Site Status

CH de Montbrison

Montbrison, , France

Site Status

Jacques Bringer

Montpellier, , France

Site Status

Marc Klein

Nancy, , France

Site Status

Michel Rodier

Nîmes, , France

Site Status

Laurence Leenhardt

Paris, , France

Site Status

Richard Marechaud

Poitiers, , France

Site Status

Brigitte Delemer

Reims, , France

Site Status

Claire Schvartz

Reims, , France

Site Status

Jean-Marc Kuhn

Rouen, , France

Site Status

Bruno Estour

Saint-Etienne, , France

Site Status

Centre Paul Strauss

Strasbourg, , France

Site Status

Hopitaux Universitaires de Strasbourg

Strasbourg, , France

Site Status

Philippe Caron

Toulouse, , France

Site Status

Pierre Lecomte

Tours, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3463

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.